45 research outputs found

    Ich habe Heimweh: Homesickness

    Get PDF

    Age at symptom onset and death and disease duration in genetic frontotemporal dementia : an international retrospective cohort study

    Get PDF
    Background: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. Methods: In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups and individual mutations. We also assessed correlations between the age at onset and at death of each individual and the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, we used mixed effects models to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried. Findings: Data were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 67 different mutations). Mean age at symptom onset and at death was 49\ub75 years (SD 10\ub70; onset) and 58\ub75 years (11\ub73; death) in the MAPT group, 58\ub72 years (9\ub78; onset) and 65\ub73 years (10\ub79; death) in the C9orf72 group, and 61\ub73 years (8\ub78; onset) and 68\ub78 years (9\ub77; death) in the GRN group. Mean disease duration was 6\ub74 years (SD 4\ub79) in the C9orf72 group, 7\ub71 years (3\ub79) in the GRN group, and 9\ub73 years (6\ub74) in the MAPT group. Individual age at onset and at death was significantly correlated with both parental age at onset and at death and with mean family age at onset and at death in all three groups, with a stronger correlation observed in the MAPT group (r=0\ub745 between individual and parental age at onset, r=0\ub763 between individual and mean family age at onset, r=0\ub758 between individual and parental age at death, and r=0\ub769 between individual and mean family age at death) than in either the C9orf72 group (r=0\ub732 individual and parental age at onset, r=0\ub736 individual and mean family age at onset, r=0\ub738 individual and parental age at death, and r=0\ub740 individual and mean family age at death) or the GRN group (r=0\ub722 individual and parental age at onset, r=0\ub718 individual and mean family age at onset, r=0\ub722 individual and parental age at death, and r=0\ub732 individual and mean family age at death). Modelling showed that the variability in age at onset and at death in the MAPT group was explained partly by the specific mutation (48%, 95% CI 35\u201362, for age at onset; 61%, 47\u201373, for age at death), and even more by family membership (66%, 56\u201375, for age at onset; 74%, 65\u201382, for age at death). In the GRN group, only 2% (0\u201310) of the variability of age at onset and 9% (3\u201321) of that of age of death was explained by the specific mutation, whereas 14% (9\u201322) of the variability of age at onset and 20% (12\u201330) of that of age at death was explained by family membership. In the C9orf72 group, family membership explained 17% (11\u201326) of the variability of age at onset and 19% (12\u201329) of that of age at death. Interpretation: Our study showed that age at symptom onset and at death of people with genetic frontotemporal dementia is influenced by genetic group and, particularly for MAPT mutations, by the specific mutation carried and by family membership. Although estimation of age at onset will be an important factor in future pre-symptomatic therapeutic trials for all three genetic groups, our study suggests that data from other members of the family will be particularly helpful only for individuals with MAPT mutations. Further work in identifying both genetic and environmental factors that modify phenotype in all groups will be important to improve such estimates. Funding: UK Medical Research Council, National Institute for Health Research, and Alzheimer's Society

    Towards real-time spatio-temporal prediction of district-level meningitis incidence in sub-Saharan Africa

    No full text
    Within an area of sub-Saharan Africa termed ‘the meningitis belt’, meningococcal meningitis epidemics are a major public health concern. The epidemic control strategy currently utilised is reactive, such that a vaccination programme is initiated in a district once a pre-defined weekly incidence threshold is exceeded. In this paper we report progress towards the development of an early warning system based on statistical modelling of district-level weekly incidence data. Four modelling approaches are considered and their forecasting performances are compared using weekly epidemiological data from Niger for the period 1986-2007. We conclude that the models under consideration are advantageous in different situations. The described three-state Markov model in which observed incidence is categorised according to policy-defined thresholds gives the most reliable short term forecasts, whereas the proposed dynamic linear model, using log-transformed weekly incidence as the response variable, gives more reliable predictions of annual epidemics

    Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events

    No full text
    Epidemiological evidence has suggested a link between beta2-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe. This is an updated systematic review

    2015 Atomic Spectrometry Update – a review of advances in X-ray fluorescence spectrometry and their applications

    No full text
    This review describes advances in the X-ray fluorescence (XRF) group of techniques published approximately between April 2014 and March 2015 and is therefore restricted to a selection of papers featuring developments in the XRF armoury. An active topic during this review period was that of imaging techniques and, more particularly of micro XRF spectrometry. Silicon-based semiconductor X-ray detectors such as SDD and Si(PIN) continue to reflect the maturity and widespread routine use of such devices. The significant expansion in studies evaluating the field use of portable XRF instrumentation in geological applications, often still proving the quality of the data, rather than adopting the technique in routine applications. New synchrotron beamlines offer previously unavailable spatial resolution and throughput for the characterisation of advanced energy materials and devices under varying temperatures and gas atmospheres. Nanomaterials feature extensively this year such as the use of nanoparticles in cancer imaging and therapy. Synchrotron radiation has become a preferred technique for the analysis of a wide range of archeological samples, artwork, museum specimens and environmental studies. There has been a substantial rise in the number of Chinese researchers investigating objects of cultural heritage, especially porcelain, glazes and glass. Advances in TXRF and related techniques continue to feature with studies on thin films and nanomaterials. Feedback on this review is most welcome and the review coordinator can be contacted using the email address provided
    corecore